Immunome is a biotechnology company focused on developing immunotherapies to treat cancer. It leverages an outcome-based immunotherapy discovery engine originally developed at MIT’s Whitehead Institute to simultaneously discover novel antigens expressed in patient tumor cells and the cognate native patient antibodies that target those antigens. Led by CEO Jane H. Hollingsworth and president and chief scientific officer Michael J. Morin, PhD, the company is advancing a pipeline of cancer therapeutics derived from that engine. Immunome plans to use proceeds from its recent financing to further develop and scale up its discovery engine and pipeline of cancer therapeutics. The company is based in Philadelphia, PA. Financially, it secured additional Series A funding in 2016–2017 to support its discovery and development efforts. Immunome is a Wynnewood-based biopharma company. The article reports Immunome raised $445,000, according to an SEC filing. The piece does not describe the company's core therapeutic programs, platform, or specific products. The article does not disclose the financing instrument, investors, valuation, or use of proceeds. No operating metrics, revenue, user numbers, or future plans were provided in the article. Additional detail would require reviewing the SEC filing or company disclosures. Immunome is a Pennsylvania biotechnology company developing therapeutics using cloned human antibodies. The company’s human antibody cloning technology is positioned for applications across Alzheimer’s disease, cancer, infectious diseases and potential bioterror countermeasures. Immunome is seeking to advance that platform and is in the process of raising $1.5 million to support its development. Its latest financing round began Jan. 4 and has raised $145,000 to date. Founder and chief science officer Dr. Scott K. Dessain is an associate professor at the Lankenau Institute for Medical Research in Wynnewood, Pennsylvania, and Timothy Pelura serves as CEO. Pelura is described on the company website as a serial life‑sciences entrepreneur with more than 35 years of experience and prior roles at Promedior, Kereos, Provasis Therapeutics, Neuron Therapeutics and Alliance Pharmaceutical Corp.

Total raised

$13M

Funding rounds

3

Latest round

Series A

Latest activity

Oct 2016